Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis
Peritoneal metastasis (PM) is an advanced stage malignancy largely refractory to modern therapy. Intraperitoneal (IP) immunotherapy offers a novel approach for the control of regional disease of the peritoneal cavity by breaking immune tolerance. These strategies include heightening T-cell response...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2018-08-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2076-393X/6/3/54 |
| _version_ | 1811300230300172288 |
|---|---|
| author | Anusha Thadi Marian Khalili William F. Morano Scott D. Richard Steven C. Katz Wilbur B. Bowne |
| author_facet | Anusha Thadi Marian Khalili William F. Morano Scott D. Richard Steven C. Katz Wilbur B. Bowne |
| author_sort | Anusha Thadi |
| collection | DOAJ |
| description | Peritoneal metastasis (PM) is an advanced stage malignancy largely refractory to modern therapy. Intraperitoneal (IP) immunotherapy offers a novel approach for the control of regional disease of the peritoneal cavity by breaking immune tolerance. These strategies include heightening T-cell response and vaccine induction of anti-cancer memory against tumor-associated antigens. Early investigations with chimeric antigen receptor T cells (CAR-T cells), vaccine-based therapies, dendritic cells (DCs) in combination with pro-inflammatory cytokines and natural killer cells (NKs), adoptive cell transfer, and immune checkpoint inhibitors represent significant advances in the treatment of PM. IP delivery of CAR-T cells has shown demonstrable suppression of tumors expressing carcinoembryonic antigen. This response was enhanced when IP injected CAR-T cells were combined with anti-PD-L1 or anti-Gr1. Similarly, CAR-T cells against folate receptor α expressing tumors improved T-cell tumor localization and survival when combined with CD137 co-stimulatory signaling. Moreover, IP immunotherapy with catumaxomab, a trifunctional antibody approved in Europe, targets epithelial cell adhesion molecule (EpCAM) and has shown considerable promise with control of malignant ascites. Herein, we discuss immunologic approaches under investigation for treatment of PM. |
| first_indexed | 2024-04-13T06:48:05Z |
| format | Article |
| id | doaj.art-f8cb359de1804ba6bdd90589e85189ed |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-04-13T06:48:05Z |
| publishDate | 2018-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-f8cb359de1804ba6bdd90589e85189ed2022-12-22T02:57:30ZengMDPI AGVaccines2076-393X2018-08-01635410.3390/vaccines6030054vaccines6030054Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal MetastasisAnusha Thadi0Marian Khalili1William F. Morano2Scott D. Richard3Steven C. Katz4Wilbur B. Bowne5Department of Surgery, Drexel University College of Medicine, Philadelphia, PA 19102, USADepartment of Surgery, Drexel University College of Medicine, Philadelphia, PA 19102, USADepartment of Surgery, Drexel University College of Medicine, Philadelphia, PA 19102, USADepartment of Obstetrics and Gynecology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USADepartment of Surgery, Boston University School of Medicine, Boston, MA 02118, USADepartment of Surgery, Drexel University College of Medicine, Philadelphia, PA 19102, USAPeritoneal metastasis (PM) is an advanced stage malignancy largely refractory to modern therapy. Intraperitoneal (IP) immunotherapy offers a novel approach for the control of regional disease of the peritoneal cavity by breaking immune tolerance. These strategies include heightening T-cell response and vaccine induction of anti-cancer memory against tumor-associated antigens. Early investigations with chimeric antigen receptor T cells (CAR-T cells), vaccine-based therapies, dendritic cells (DCs) in combination with pro-inflammatory cytokines and natural killer cells (NKs), adoptive cell transfer, and immune checkpoint inhibitors represent significant advances in the treatment of PM. IP delivery of CAR-T cells has shown demonstrable suppression of tumors expressing carcinoembryonic antigen. This response was enhanced when IP injected CAR-T cells were combined with anti-PD-L1 or anti-Gr1. Similarly, CAR-T cells against folate receptor α expressing tumors improved T-cell tumor localization and survival when combined with CD137 co-stimulatory signaling. Moreover, IP immunotherapy with catumaxomab, a trifunctional antibody approved in Europe, targets epithelial cell adhesion molecule (EpCAM) and has shown considerable promise with control of malignant ascites. Herein, we discuss immunologic approaches under investigation for treatment of PM.http://www.mdpi.com/2076-393X/6/3/54intraperitoneal immunotherapyvaccinesCAR-T cellsascitescarcinoembryonic antigenfolate receptor αdendritic cellsperitonealmetastasis |
| spellingShingle | Anusha Thadi Marian Khalili William F. Morano Scott D. Richard Steven C. Katz Wilbur B. Bowne Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis Vaccines intraperitoneal immunotherapy vaccines CAR-T cells ascites carcinoembryonic antigen folate receptor α dendritic cells peritoneal metastasis |
| title | Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis |
| title_full | Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis |
| title_fullStr | Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis |
| title_full_unstemmed | Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis |
| title_short | Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis |
| title_sort | early investigations and recent advances in intraperitoneal immunotherapy for peritoneal metastasis |
| topic | intraperitoneal immunotherapy vaccines CAR-T cells ascites carcinoembryonic antigen folate receptor α dendritic cells peritoneal metastasis |
| url | http://www.mdpi.com/2076-393X/6/3/54 |
| work_keys_str_mv | AT anushathadi earlyinvestigationsandrecentadvancesinintraperitonealimmunotherapyforperitonealmetastasis AT mariankhalili earlyinvestigationsandrecentadvancesinintraperitonealimmunotherapyforperitonealmetastasis AT williamfmorano earlyinvestigationsandrecentadvancesinintraperitonealimmunotherapyforperitonealmetastasis AT scottdrichard earlyinvestigationsandrecentadvancesinintraperitonealimmunotherapyforperitonealmetastasis AT stevenckatz earlyinvestigationsandrecentadvancesinintraperitonealimmunotherapyforperitonealmetastasis AT wilburbbowne earlyinvestigationsandrecentadvancesinintraperitonealimmunotherapyforperitonealmetastasis |